-
1.发明申请
公开(公告)号：WO2021247291A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/034085
申请日：2021-05-25
Applicant: GLYKON TECHNOLOGIES GROUP, LLC
Inventor： CLOUATRE, Daniel E.
IPC: A61J1/14 , A61K31/00 , A61K31/047 , A61B5/14551 , A61K31/194 , G16H20/10 , G16H70/40
Abstract: Provided is a method of treating a subject, including: (i) determining an initial level of blood oxygen saturation in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, wherein HCA is (−)-hydroxycitric acid, a salt thereof, or a derivative thereof, thereby increasing blood oxygen saturation. Provided is a kit including HCA and instructions directing a subject to ingest the HCA if the subject is determined to have unhealthily low blood oxygen saturation. Provided is a method of treating a subject, including: (i) determining an initial level of blood hemoglobin in the subject, and (ii) administering to the subject a therapeutically effective amount of a formulation including HCA, thereby increasing blood hemoglobin.
-
2.发明申请A SYNERGISTIC COMPOSITION OF (-)-HYDROXYCITRIC ACID WITH MONOTERPENE AND A METHOD TO ENHANCE SATIETY 审中-公开（ - ） - 羟基酸与单酯的协同组合和一种增强唾液酸的方法
公开(公告)号：WO2011051899A1
公开(公告)日：2011-05-05
申请号：PCT/IB2010/054884
申请日：2010-10-28
Applicant: GLYKON TECHNOLOGIES GROUP, LLC , PFIZER INC. , CLOUATRE, Daniel, Elliott , CLOUATRE, Dallas, Lavoe , TAYLOR, Jeff , WHITE, Tyler
Inventor： CLOUATRE, Daniel, Elliott , CLOUATRE, Dallas, Lavoe , TAYLOR, Jeff , WHITE, Tyler
IPC: A61K31/194 , A61K31/16 , A61P3/04 , A61K31/01 , A61K31/225
CPC classification number: A61K9/0095 , A23L33/10 , A23L33/105 , A61K9/4875 , A61K31/01 , A61K31/16 , A61K31/194 , A61K31/225 , A61K2300/00
Abstract: The present disclosure provides synergistic composition comprising (-)-hydroxycitric acid, its salts, amides and esters in conjunction with monoterpenes for enhancing satiety. The disclosure is also related to the use of synergistic composition in food and pharmaceutical compositions. The present disclosure helps in controlling obesity by enhancing satiety.
Abstract translation: 本公开内容提供包含（ - ） - 羟基柠檬酸，其盐，酰胺和酯与单萜一起用于增强饱腹感的协同组合物。 本公开还涉及在食品和药物组合物中使用协同组合物。 本公开通过增强饱腹感有助于控制肥胖。
-
公开(公告)号：WO2021247289A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/034079
申请日：2021-05-25
Applicant: GLYKON TECHNOLOGIES GROUP, LLC
Inventor： CLOUATRE, Daniel E.
Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.
-
公开(公告)号：WO2005025544A1
公开(公告)日：2005-03-24
申请号：PCT/US2004/029471
申请日：2004-09-10
Applicant: GLYKON TECHNOLOGIES GROUP, LLC , CLOUATRE, Dallas, L. , DUNN, James, M.
Inventor： CLOUATRE, Dallas, L. , DUNN, James, M.
IPC: A61K9/28
CPC classification number: A61K9/2866 , A61K9/2846 , A61K9/4891
Abstract: The present invention provides stable encapsulated (-)-hydroxycitric acid ("HCA") dosage unit forms, uses thereof, as well as and methods of making the same. In particular, HCA and the salts, esters and amides of HCA according to the invention are delivered via enteric vehicles, such as enteric-coated tablets, and also enteric and enteric-coated capsules and soft gelatin capsules (softgels). Enteric-coatings may be applied externally to the HCA-containing dosage unit form or, in the case of capsules and soft gelatin capsules, the enteric compound also may be incorporated into the gelatin shell to yield an HCA-containing dosage unit form of the invention. The HCA-containing compositions are protected against acid degradation, lactonization and undesirable ligand binding in select environments. The invention provides HCA-containing dosage unit forms useful to prevent or reduce the symptoms associated with a disease, disorder or condition such as obesity, weight gain, hunger, hyperlipemia, and postprandial lipemia.
Abstract translation: 本发明提供稳定的包封的（ - ） - 羟基柠檬酸（“HCA”）剂量单位形式及其用途，以及制备它们的方法。 特别地，根据本发明的HCA和HCA的盐，酯和酰胺通过肠溶媒介物如肠溶衣片剂以及肠溶和肠溶衣胶囊和软明胶胶囊（软胶囊）递送。 肠溶衣可以外用于含HCA的剂量单位形式，或者在胶囊和软明胶胶囊的情况下，也可以将肠溶化合物掺入明胶壳中以产生本发明的含HCA的剂量单位形式 。 保护含HCA的组合物在选择的环境中被防止酸降解，内酯化和不期望的配体结合。 本发明提供了含有HCA的剂量单位形式，可用于预防或减少与诸如肥胖，体重增加，饥饿，高脂血症和餐后脂血症等疾病，病症或病症相关的症状。
-
5.发明申请
公开(公告)号：WO2010150072A1
公开(公告)日：2010-12-29
申请号：PCT/IB2010/001499
申请日：2010-06-22
Inventor： CLOUATRE, Daniel, Elliot , CLOUATRE, Dallas, Lavoe
CPC classification number: A61K31/194 , A61K31/343 , A61K36/42 , A61K45/06 , A61K2300/00
Abstract: The present disclosure discloses a synergistic combination comprising (-) - hydroxycitric acid, bitter melon extract and sesame seed lignans extract to enhance blood glucose and insulin metabolism. The synergistic combination also reduces reactive hypoglycemia in those who are insulin resistant.
Abstract translation: 本公开公开了包含（ - ） - 羟基柠檬酸，苦瓜提取物和芝麻籽木脂素提取物以增强血糖和胰岛素代谢的协同组合。 协同组合也能降低胰岛素抵抗者的反应性低血糖。
-
Patent Agency Ranking6.发明申请TREATING CACHEXIA AND EXCESSIVE CATABOLISM WITH (-)-HYDROXYCITRIC ACID 审中-公开用（ - ） - 羟基酸处理高速公路和超临界催化剂
公开(公告)号：WO2005007152A1
公开(公告)日：2005-01-27
申请号：PCT/US2004/021542
申请日：2004-07-02
Applicant: GLYKON TECHNOLOGIES GROUP, LLC , CLOUATRE, Dallas, L.
Inventor： CLOUATRE, Dallas, L.
IPC: A61K31/19
CPC classification number: A61K31/19 , A61K31/366
Abstract: This invention relates to compositions containing (-)-hydroxycitric acid useful for treating and ameliorating cachexia, health-threatening catabolism and unhealthful weight loss, such as is characteristic of sarcopenia. Specifically, the invention provides a method useful for treating and ameliorating cachexia, health-threatening catabolism and unhealthful weight loss, such as is characteristic of sarcopenia, without disturbing hormonal and central mechanisms of metabolic regulation.
Abstract translation: 本发明涉及含有（ - ） - 羟基柠檬酸的组合物，其用于治疗和改善恶病质，具有健康威胁的分解代谢和不健康的体重减轻，例如肌肉减少症的特征。 具体地说，本发明提供了一种有助于治疗和改善恶病质，健康威胁性分解代谢和不健康体重减轻的方法，例如肌肉减少症的特征，而不影响代谢调节的激素和中枢机制。
-
公开(公告)号：WO2018080795A1
公开(公告)日：2018-05-03
申请号：PCT/US2017/056111
申请日：2017-10-11
Applicant: GLYKON TECHNOLOGIES GROUP, LLC
Inventor： CLOUATRE, Dallas L. , CLOUATRE, Daniel E.
Abstract: A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.
Abstract translation: 公开了一种胶囊口服递送系统。 该系统包括完全封闭内容物的外胶囊或包封内容物的由羟丙基甲基纤维素（HPMC）组成的硬壳。 形成外胶囊内含量的液体制剂由羟基柠檬酸（HCA）盐，水和甘油组成，其中HCA完全溶于水和甘油中，甘油可以是胶囊中存在的唯一组分，其中 可以在治疗方法中给患者施用以在重复施用时引起体重减轻。
-
公开(公告)号：WO2005030195A1
公开(公告)日：2005-04-07
申请号：PCT/US2004/030534
申请日：2004-09-20
Applicant: GLYKON TECHNOLOGIES GROUP, LLC , CLOUATRE, Dallas, L. , DUNN, James, M.
Inventor： CLOUATRE, Dallas, L. , DUNN, James, M.
IPC: A61K31/191
CPC classification number: A61K9/0095 , A61K9/2009 , A61K9/205 , A61K31/191 , A61K31/194 , A61K2300/00
Abstract: The inventors have discovered that food and pharmaceutical compositions containing (-)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for preventing and treating diverse conditions, e.g., stomach ulcers, portal hypertension, liver dysfunction, diabetes and obesity. The invention provides methods for delaying gastric emptying and increasing receptive relaxation in individuals. The invention also provides methods of preventing or treating disorders or conditions related to aberrant gastric emptying and receptive relaxation.
Abstract translation: 本发明人已经发现含有（ - ） - 羟基柠檬酸，其盐，酰胺和酯的食品和药物组合物可用于延迟胃排空和增加用于预防和治疗多种病症的接受松弛。 本发明提供含有HCA的化合物，其可用于延迟胃排空并增加用于预防和治疗多种病症如胃溃疡，门静脉高压，肝功能障碍，糖尿病和肥胖症的接受松弛。 本发明提供了延缓胃排空并增加个体接受放松的方法。 本发明还提供了预防或治疗与异常胃排空和接受放松相关的病症或病症的方法。
-
公开(公告)号：WO2021247293A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/034093
申请日：2021-05-25
Applicant: GLYKON TECHNOLOGIES GROUP, LLC
Inventor： CLOUATRE, Daniel E.
IPC: A61K31/225 , A61K47/10 , A61K47/12 , A61K31/194 , A61P25/16 , A61P3/00
Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.
-
10.发明申请MONOMERIC BIMETAL HYDROXYCITRIC ACID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME 审中-公开单体双甲羟基酸化合物及其制备和使用方法
公开(公告)号：WO2018049216A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050759
申请日：2017-09-08
Applicant: GLYKON TECHNOLOGIES GROUP, LLC
Inventor： CLOUATRE, Daniel E. , BANGUN, Nimpan , CLOUATRE, Dallas L.
IPC: A61K31/19 , A61K31/185 , A61K31/194 , C07C59/235 , C07C59/245 , C07C59/265
Abstract: Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X3(HCA)2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.
Abstract translation: 提供了单体双金属羟基柠檬酸（HCA）化合物。 主题化合物包括与C2和C3的羧酸键合的二价金属（X）和与C1的羧酸键合的单价金属（Y）。 还提供了从二聚原料（例如X3（HCA）2）制备主题化合物的方法，其包括酸化二聚体以产生随后用YOH碱中和的单体中间体。 提供了减轻受试者中与目标疾病或病症相关的至少一种症状的方法。 还提供了包含可用于各种治疗应用的目标单体双金属HCA化合物的组合物。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.011 seconds)
